CN103127156A - 对延长的激素避孕方案中突破性出血的控制 - Google Patents

对延长的激素避孕方案中突破性出血的控制 Download PDF

Info

Publication number: CN103127156A
Authority: CN; China
Prior art keywords: days; women; preparation; administration; cycle
Prior art date: 2004-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN2012105794658A

Other languages

English (en)

Chinese (zh)

Inventor

安德烈亚斯·萨克塞

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-30

Filing date

2005-04-29

Publication date

2013-06-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103127156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-29 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2013-06-05 Publication of CN103127156A publication Critical patent/CN103127156A/zh

Status Pending legal-status Critical Current

Links

239000003433 contraceptive agent Substances 0.000 title claims abstract description 19
206010027514 Metrorrhagia Diseases 0.000 title claims description 34
229940011871 estrogen Drugs 0.000 claims description 23
239000000262 estrogen Substances 0.000 claims description 23
238000002360 preparation method Methods 0.000 claims description 21
239000000902 placebo Substances 0.000 claims description 10
229940068196 placebo Drugs 0.000 claims description 10
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 9
229960004845 drospirenone Drugs 0.000 claims description 9
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 5
230000000740 bleeding effect Effects 0.000 abstract description 21
230000003054 hormonal effect Effects 0.000 abstract description 2
229940124558 contraceptive agent Drugs 0.000 abstract 1
208000032843 Hemorrhage Diseases 0.000 description 65
239000006187 pill Substances 0.000 description 41
229940127234 oral contraceptive Drugs 0.000 description 34
239000003539 oral contraceptive agent Substances 0.000 description 34
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 21
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 21
229960002568 ethinylestradiol Drugs 0.000 description 21
208000034158 bleeding Diseases 0.000 description 20
239000000583 progesterone congener Substances 0.000 description 19
239000000047 product Substances 0.000 description 18
238000000034 method Methods 0.000 description 17
238000011160 research Methods 0.000 description 16
230000000694 effects Effects 0.000 description 15
229940088597 hormone Drugs 0.000 description 12
239000005556 hormone Substances 0.000 description 12
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 11
229960004400 levonorgestrel Drugs 0.000 description 11
230000005906 menstruation Effects 0.000 description 10
208000002874 Acne Vulgaris Diseases 0.000 description 8
206010019233 Headaches Diseases 0.000 description 8
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 8
238000010521 absorption reaction Methods 0.000 description 8
206010000496 acne Diseases 0.000 description 8
231100000869 headache Toxicity 0.000 description 8
229960001652 norethindrone acetate Drugs 0.000 description 8
230000002085 persistent effect Effects 0.000 description 8
208000005171 Dysmenorrhea Diseases 0.000 description 7
206010013935 Dysmenorrhoea Diseases 0.000 description 7
208000007106 menorrhagia Diseases 0.000 description 7
229960004976 desogestrel Drugs 0.000 description 6
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
201000009273 Endometriosis Diseases 0.000 description 5
206010036049 Polycystic ovaries Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 5
230000002175 menstrual effect Effects 0.000 description 5
230000000737 periodic effect Effects 0.000 description 5
201000010065 polycystic ovary syndrome Diseases 0.000 description 5
206010047998 Withdrawal bleed Diseases 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229960003309 dienogest Drugs 0.000 description 4
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000003821 menstrual periods Effects 0.000 description 4
229960000417 norgestimate Drugs 0.000 description 4
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 4
230000035935 pregnancy Effects 0.000 description 4
230000002265 prevention Effects 0.000 description 4
208000000450 Pelvic Pain Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
230000002254 contraceptive effect Effects 0.000 description 3
229960000978 cyproterone acetate Drugs 0.000 description 3
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 3
229960002941 etonogestrel Drugs 0.000 description 3
230000003203 everyday effect Effects 0.000 description 3
229960005352 gestodene Drugs 0.000 description 3
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 3
238000012360 testing method Methods 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004899 motility Effects 0.000 description 2
229940053934 norethindrone Drugs 0.000 description 2
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
229950008546 trimegestone Drugs 0.000 description 2
JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 description 2
ISHXLNHNDMZNMC-VTKCIJPMSA-N (3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C\1 ISHXLNHNDMZNMC-VTKCIJPMSA-N 0.000 description 1
WNSDZLZVSSOOCA-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WNSDZLZVSSOOCA-WOMZHKBXSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010006313 Breast tenderness Diseases 0.000 description 1
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010046788 Uterine haemorrhage Diseases 0.000 description 1
206010046910 Vaginal haemorrhage Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical group C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
230000008217 follicular development Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960001910 lynestrenol Drugs 0.000 description 1
230000035800 maturation Effects 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
229960002667 norelgestromin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
231100000279 safety data Toxicity 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)
Steroid Compounds (AREA)

CN2012105794658A 2004-04-30 2005-04-29 对延长的激素避孕方案中突破性出血的控制 Pending CN103127156A (zh)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date
US56644304P	2004-04-30	2004-04-30
US60/566,443		2004-04-30
US57502404P	2004-05-28	2004-05-28
US60/575,024		2004-05-28
US57719904P	2004-06-07	2004-06-07
US60/577,199		2004-06-07
US63838004P	2004-12-27	2004-12-27
US60/638,380		2004-12-27
US66006805P	2005-03-10	2005-03-10
US60/660,068		2005-03-10

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CNA200580013899XA Division CN1950092A (zh)	2004-04-30	2005-04-29	对延长的激素避孕方案中突破性出血的控制

Publications (1)

Publication Number	Publication Date
CN103127156A true CN103127156A (zh)	2013-06-05

Family

ID=35056905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN2012105794658A Pending CN103127156A (zh)	2004-04-30	2005-04-29	对延长的激素避孕方案中突破性出血的控制

Country Status (29)

Country	Link
US (3)	US8163721B2 (2)
EP (1)	EP1747001B1 (2)
JP (4)	JP2007535519A (2)
KR (4)	KR20070004919A (2)
CN (1)	CN103127156A (2)
AR (1)	AR048722A1 (2)
AU (1)	AU2005237255B2 (2)
BR (1)	BRPI0510493A (2)
CA (1)	CA2562296A1 (2)
CR (1)	CR8709A (2)
DK (1)	DK1747001T3 (2)
EA (2)	EA031227B1 (2)
EC (1)	ECSP066999A (2)
ES (1)	ES2704999T3 (2)
HU (1)	HUE041475T2 (2)
IL (1)	IL178458A (2)
LT (1)	LT1747001T (2)
MX (1)	MXPA06012567A (2)
MY (1)	MY151322A (2)
NO (1)	NO341685B1 (2)
NZ (1)	NZ586107A (2)
PA (1)	PA8631801A1 (2)
PE (1)	PE20060467A1 (2)
SG (2)	SG152288A1 (2)
SI (1)	SI1747001T1 (2)
SV (1)	SV2006002100A (2)
TW (1)	TWI374735B (2)
UY (1)	UY28875A1 (2)
WO (1)	WO2005105103A2 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108025014A (zh) *	2015-06-23	2018-05-11	莱昂实验室制药股份有限公司	用于过重女性患者的基于屈螺酮的避孕药

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
MY151322A (en) *	2004-04-30	2014-05-15	Bayer Ip Gmbh	Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en)	2004-10-07	2007-05-17	Duramed Pharmaceuticals, Inc.	Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) *	2005-10-17	2007-04-19	Doris Huebler	Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) *	2007-03-01	2008-10-08	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) *	2007-03-02	2008-09-04	Bayer Schering Pharma Aktiengesellschaft	Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
GB2475013A (en) *	2008-09-16	2011-05-04	Playtex Products Llc	Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
WO2010042607A1 (en)	2008-10-08	2010-04-15	Agile Therapeutics, Inc	Transdermal delivery
EP2343979B1 (en)	2008-10-08	2020-04-08	Agile Therapeutics, Inc.	Transdermal delivery
US9192614B2 (en)	2008-10-08	2015-11-24	Agile Therapeutics, Inc.	Contraceptive transdermal delivery of hormones
WO2010111488A1 (en)	2009-03-27	2010-09-30	Agile Therapeutics, Inc.	Transdermal delivery
AR081670A1 (es)	2010-06-29	2012-10-10	Leon Farma Sa Lab	Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en)	2010-07-28	2022-06-07	Laboratorios Leon Farma Sa	Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en)	2010-07-28	2020-12-01	Laboratorios Leon Farma Sa	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en)	2010-07-28	2017-03-28	Laboratorios Leon Farma Sa	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Process for the preparation of estetrol
EP3701944B1 (en)	2015-06-18	2021-12-08	Estetra SRL	Orodispersible dosage unit containing an estetrol component
CU24523B1 (es)	2015-06-18	2021-06-08	Estetra Sprl	Unidad de dosificación orodispersable que contiene un componente estetrol
MA44206B1 (fr)	2015-06-18	2021-04-30	Estetra Sprl	Comprimé orodispersible comprenant estetrol
LT3310345T (lt)	2015-06-18	2021-06-25	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
CA3178291A1 (en)	2016-08-05	2018-04-12	Estetra Srl	Method for the management of dysmenorrhea and menstrual pain
WO2018060501A2 (en)	2016-09-30	2018-04-05	Myovant Sciences Gmbh	Methods of treating uterine fibroids and endometriosis
TWI801561B (zh)	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
EP3781171B1 (en)	2018-04-19	2022-02-09	Estetra SRL	Compounds and their uses for alleviating menopause-associated symptoms
TWI893101B (zh)	2020-04-16	2025-08-11	比利時商埃斯特拉有限責任公司	具有降低之副作用之避孕組成物
BR112022023937A2 (pt)	2020-05-29	2022-12-27	Myovant Sciences Gmbh	Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
US12138270B2 (en)	2021-09-07	2024-11-12	Millicent Pharma Limited	Contraceptive regimen including reduced level of estrogen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1455681A (zh) *	2000-09-14	2003-11-12	舍林股份公司	避孕方法及用于其的给药形式

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5244096A (en)	1988-04-22	1993-09-14	Stoner Fred L	Preventive treatment kit against sexually transmitted disease
AU3473193A (en)	1992-01-17	1993-08-03	Procter & Gamble Company, The	Treatment for atherosclerosis
DE4344462C2 (de)	1993-12-22	1996-02-01	Schering Ag	Zusammensetzung für die Empfängnisverhütung
US5552394A (en)	1994-07-22	1996-09-03	The Medical College Of Hampton Roads	Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
PT956024E (pt) *	1996-07-26	2004-10-29	Wyeth Corp	Metodo contraceptivo oral monofasico e estojo ("kit") compreendendo uma combinacao de uma progestina e estrogenio
US6451778B1 (en) *	1996-07-26	2002-09-17	Wyeth	Oral contraceptive
US5842441A (en)	1996-08-26	1998-12-01	Pharmalett Denmark A/S	Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en)	1997-06-23	1999-04-27	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) *	1997-09-11	2001-09-13	Hesch Rolf Dieter	Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6787531B1 (en) *	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
DK1380301T3 (da)	1999-08-31	2009-04-20	Bayer Schering Pharma Ag	Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
CO5271709A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) *	2000-01-14	2003-11-25	Sterix Limited	Composition
IL145876A0 (en)	2000-10-17	2002-07-25	Pfizer Prod Inc	Methods and kits for improving vascular health
US20020193356A1 (en) *	2001-05-23	2002-12-19	Van Beek Agatha Antonia Magdalena	Means and method for hormonal contraception
US20030018018A1 (en)	2001-07-10	2003-01-23	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en)	2004-04-30	2014-05-15	Bayer Ip Gmbh	Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en)	2004-07-30	2013-08-06	Bayer Pharma AG	Method for treatment of dysmenorrhea

2005
- 2005-04-19 MY MYPI20051728 patent/MY151322A/en unknown
- 2005-04-27 UY UY28875A patent/UY28875A1/es not_active IP Right Cessation
- 2005-04-29 LT LTEP05740127.5T patent/LT1747001T/lt unknown
- 2005-04-29 SI SI200532240T patent/SI1747001T1/sl unknown
- 2005-04-29 EA EA201200377A patent/EA031227B1/ru not_active IP Right Cessation
- 2005-04-29 JP JP2007509994A patent/JP2007535519A/ja not_active Withdrawn
- 2005-04-29 KR KR1020067022523A patent/KR20070004919A/ko not_active Ceased
- 2005-04-29 KR KR1020157012286A patent/KR101812160B1/ko not_active Expired - Lifetime
- 2005-04-29 SV SV2005002100A patent/SV2006002100A/es unknown
- 2005-04-29 MX MXPA06012567A patent/MXPA06012567A/es active IP Right Grant
- 2005-04-29 TW TW094113795A patent/TWI374735B/zh not_active IP Right Cessation
- 2005-04-29 HU HUE05740127A patent/HUE041475T2/hu unknown
- 2005-04-29 WO PCT/EP2005/004777 patent/WO2005105103A2/en not_active Ceased
- 2005-04-29 AU AU2005237255A patent/AU2005237255B2/en not_active Expired
- 2005-04-29 KR KR1020167035558A patent/KR20160150113A/ko not_active Ceased
- 2005-04-29 DK DK05740127.5T patent/DK1747001T3/en active
- 2005-04-29 BR BRPI0510493-9A patent/BRPI0510493A/pt not_active Application Discontinuation
- 2005-04-29 NZ NZ586107A patent/NZ586107A/en not_active IP Right Cessation
- 2005-04-29 ES ES05740127T patent/ES2704999T3/es not_active Expired - Lifetime
- 2005-04-29 CA CA002562296A patent/CA2562296A1/en not_active Abandoned
- 2005-04-29 EA EA200601908A patent/EA016625B1/ru not_active IP Right Cessation
- 2005-04-29 CN CN2012105794658A patent/CN103127156A/zh active Pending
- 2005-04-29 EP EP05740127.5A patent/EP1747001B1/en not_active Revoked
- 2005-04-29 SG SG200902990-1A patent/SG152288A1/en unknown
- 2005-04-29 KR KR1020137001481A patent/KR20130022425A/ko not_active Ceased
- 2005-04-29 SG SG10201701904TA patent/SG10201701904TA/en unknown
- 2005-05-02 AR ARP050101738A patent/AR048722A1/es not_active Application Discontinuation
- 2005-05-02 US US11/118,779 patent/US8163721B2/en not_active Expired - Fee Related
- 2005-05-03 PE PE2005000490A patent/PE20060467A1/es not_active Application Discontinuation
- 2005-05-03 PA PA20058631801A patent/PA8631801A1/es unknown
2006
- 2006-10-05 IL IL178458A patent/IL178458A/en active IP Right Grant
- 2006-10-25 CR CR8709A patent/CR8709A/es not_active Application Discontinuation
- 2006-11-13 EC EC2006006999A patent/ECSP066999A/es unknown
- 2006-11-28 NO NO20065499A patent/NO341685B1/no unknown
2012
- 2012-04-17 US US13/448,585 patent/US20120202779A1/en not_active Abandoned
- 2012-10-12 JP JP2012227416A patent/JP6134491B2/ja not_active Expired - Lifetime
2015
- 2015-03-09 US US14/642,096 patent/US20150174142A1/en not_active Abandoned
- 2015-06-23 JP JP2015126043A patent/JP6153967B2/ja not_active Expired - Lifetime
2016
- 2016-12-13 JP JP2016241318A patent/JP2017048253A/ja not_active Withdrawn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1455681A (zh) *	2000-09-14	2003-11-12	舍林股份公司	避孕方法及用于其的给药形式

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
I. WIEGRATZ等: "Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives", 《CONTRACEPTION》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108025014A (zh) *	2015-06-23	2018-05-11	莱昂实验室制药股份有限公司	用于过重女性患者的基于屈螺酮的避孕药

Also Published As

Publication number	Publication date
IL178458A (en)	2016-08-31
SG10201701904TA (en)	2017-05-30
CR8709A (es)	2007-08-28
JP6134491B2 (ja)	2017-05-24
HUE041475T2 (hu)	2019-05-28
DK1747001T3 (en)	2019-02-04
SV2006002100A (es)	2006-02-15
US20150174142A1 (en)	2015-06-25
AR048722A1 (es)	2006-05-17
CA2562296A1 (en)	2005-11-10
KR20160150113A (ko)	2016-12-28
EA031227B1 (ru)	2018-12-28
NO20065499L (no)	2006-11-29
JP2015187157A (ja)	2015-10-29
UY28875A1 (es)	2005-11-30
AU2005237255B2 (en)	2011-07-07
JP2007535519A (ja)	2007-12-06
JP2017048253A (ja)	2017-03-09
JP2013018787A (ja)	2013-01-31
EA201200377A8 (ru)	2018-01-31
WO2005105103A3 (en)	2006-09-08
KR20130022425A (ko)	2013-03-06
TWI374735B (en)	2012-10-21
IL178458A0 (en)	2008-04-13
AU2005237255A1 (en)	2005-11-10
ES2704999T3 (es)	2019-03-21
SG152288A1 (en)	2009-05-29
EP1747001A2 (en)	2007-01-31
BRPI0510493A (pt)	2007-11-13
US8163721B2 (en)	2012-04-24
PE20060467A1 (es)	2006-06-11
WO2005105103A2 (en)	2005-11-10
NO341685B1 (no)	2017-12-18
MY151322A (en)	2014-05-15
NZ586107A (en)	2012-05-25
US20120202779A1 (en)	2012-08-09
KR20150058555A (ko)	2015-05-28
EP1747001B1 (en)	2018-10-10
EA200601908A1 (ru)	2007-04-27
TW200603781A (en)	2006-02-01
SI1747001T1 (sl)	2019-02-28
ECSP066999A (es)	2006-12-29
PA8631801A1 (es)	2006-11-09
KR20070004919A (ko)	2007-01-09
MXPA06012567A (es)	2006-12-15
EA201200377A1 (ru)	2012-08-30
EA016625B1 (ru)	2012-06-29
US20050250747A1 (en)	2005-11-10
KR101812160B1 (ko)	2017-12-27
LT1747001T (lt)	2019-01-25
JP6153967B2 (ja)	2017-06-28

Legal Events

Date	Code	Title	Description
2013-06-05	C06	Publication
2013-06-05	PB01	Publication
2013-07-10	C10	Entry into substantive examination
2013-07-10	SE01	Entry into force of request for substantive examination
2014-03-07	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1186108 Country of ref document: HK
2017-09-08	CB03	Change of inventor or designer information
2017-09-08	CB03	Change of inventor or designer information	Inventor after: Sachse Andreas Inventor after: PJSulak Inventor before: Sachse Andreas
2017-09-12	TA01	Transfer of patent application right
2017-09-12	TA01	Transfer of patent application right	Effective date of registration: 20170824 Address after: German Monheim Applicant after: Bayer Pharma Aktiengesellschaft Address before: Berlin Applicant before: Bayer Pharma AG
2018-08-28	WD01	Invention patent application deemed withdrawn after publication
2018-08-28	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20130605
2019-12-06	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1186108 Country of ref document: HK

Publication	Publication Date	Title
JP6153967B2 (ja)	2017-06-28	延長されたホルモン避妊法における破綻出血の管理
CN100377713C (zh)	2008-04-02	避孕组合物
NZ312081A (en)	1999-04-29	A two stage hormonal contraception (fertility control) in at least 30 daily doses containing an oestrogen (estrogen) preparation and a kit therefore.
CA2392841A1 (en)	2003-01-10	Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
HK1246664A1 (en)	2018-09-14	Management of breakthrough bleeding in extended hormonal contraceptive regimens
AU2011226911B2 (en)	2014-06-19	Management of breakthrough bleeding in extended hormonal contraceptive regimens
HK1186108A (en)	2014-03-07	Management of breakthrough bleeding in extended hormonal contraceptive regimens
CN107875388A (zh)	2018-04-06	对延长的激素避孕方案中突破性出血的控制
MXPA98000026A (en)		Combined pharmaceutical preparation, equipment and method for hormo contraception
HK1076716B (en)	2010-10-22	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
HK1076716A1 (zh)	2006-01-27	预防怀孕和减少经期前症状的口服避孕药
HK1102771A (en)	2007-12-07	Management of breakthrough bleeding in extended hormonal contraceptive regimens
MXPA96004440A (en)	1997-12-01	Preparation of a pharmaceutical combination for oven contraception
HK1077743B (en)	2009-04-24	Composition for contraception

CN103127156A - 对延长的激素避孕方案中突破性出血的控制 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (10)

Related Parent Applications (1)

Publications (1)

Family

ID=35056905

Family Applications (1)

Country Status (29)

Cited By (1)

Families Citing this family (27)

Citations (1)

Family Cites Families (18)

Patent Citations (1)

Non-Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events